Press Releases

Cancer Immunotherapy Market Size 2022 to 2030: Vision Research Reports

Share This Article

The report on the global cancer immunotherapy market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2022 to 2030. The report provides the overall revenue of the global cancer immunotherapy market for the period 2017–2030, considering 2021 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global cancer immunotherapy market for the forecast period.

The global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030 from valued at US$ 60.1 billion in 2020, growing at a CAGR of 10.6% from 2021 to 2030. Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and a reduction in the recurrence rate of tumor post chemotherapy.

Get the sample pages of report@ https://www.visionresearchreports.com/report/sample/38822

Report Coverage

Report Scope Details
Market Size US$ 130.6 Bn by 2030
Growth Rate CAGR of 10.6% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, cancer type
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned F. Hoffmann-La Roche, Ltd; AstraZeneca; Bristol-Myers Squibb Company; Pfizer, Inc.; Merck & Co., Inc.; Novartis AG.

Major Reasons to Buy this Report

This market report is the perfect presentation of the qualitative and quantitative analysis of the market according to categorization considering economic and non-economic factors.

  • It also provides provision of market value (USD Million) data for every segment and sub-segment.
  • This report further focuses on prominent regions and segmentation of the market, which is anticipated to record the rapid growth and dominate the market.
  • Market analysis is done on the basis of major regions covering consumption of the product in particular region and factors affecting the market growth in every region.
  • This market report further sheds light on competitive landscape, which indicates the place of the prominent key players in the market. It also covers a few crucial market strategies followed by the major players of the market such as partnerships, new service launches, business expansions and acquisitions of the companies profiled during last five years.
  • This market study sheds light on a wide range of company profiles, which contain company insights, SWOT analysis for the prominent industry players, company overview and product benchmarking.
  • The present and future market outlook of the industry is also mentioned in this unique market report along with recent development such as drivers, opportunities, challenges and market restricting factors of developed and rising regions.
  • This market report is the unique depiction of porter’s five forces analysis, which is performed thorough analysis of the market perspectives.  Insights into market scenario is provided through value chain
  •  It further focuses on growth opportunities of upcoming years and depicts market scenario along with market dynamics.
  • This market report also provides six month post-sales analyst support.

Purchase This Report@ https://www.visionresearchreports.com/report/cart/38822

Customization of the Report

Please feel free to contact our sales team in case of any Query or Customization Requirements. Our expert team will give you right solutions for your query.

Key Players

 Amgen Inc.; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Co.; Merck and Co.; Novartis; and Pfizer.

Market Segmentation

  • By Product
    • Monoclonal Antibodies
    • Immunomodulators
    • Oncolytic Viral Therapies and Cancer Vaccines
  • By Cancer Type
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head and Neck Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
  • Regional
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • U.A.E.

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Cancer Immunotherapy Market, By Product

7.1.  Cancer Immunotherapy Market, by Product, 2021-2030

7.1.1.    Monoclonal Antibodies

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Immunomodulators

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Oncolytic Viral Therapies and Cancer Vaccines

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Cancer Immunotherapy Market, By Cancer Type

8.1.  Cancer Immunotherapy Market, by Cancer Type, 2021-2030

8.1.1.    Lung Cancer

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Breast Cancer

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Colorectal Cancer

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Melanoma

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Prostate Cancer

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    Head and Neck Cancer

8.1.6.1.        Market Revenue and Forecast (2017-2030)

8.1.7.    Ovarian Cancer

8.1.7.1.        Market Revenue and Forecast (2017-2030)

8.1.8.    Pancreatic Cancer

8.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Product (2017-2030)

9.1.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Product (2017-2030)

9.2.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Product (2017-2030)

9.3.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Product (2017-2030)

9.4.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Product (2017-2030)

9.5.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

Chapter 10.  Company Profiles

10.1.              Amgen Inc.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              AstraZeneca

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              F. Hoffman La Roche

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Bayer AG

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Bristol-Myers Squibb

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Eli Lilly and Co.; Merck

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Novartis

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Pfizer

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Purchase This Report@ https://www.visionresearchreports.com/report/cart/38822

Related Articles

Back to top button